sur Immunic AG
Immunic, Inc. to Release Q3 2024 Financial Results and Corporate Update
Immunic, Inc., a biotechnology firm focused on small molecule therapies for chronic inflammatory and autoimmune diseases, will announce its financial results for the third quarter of 2024 on November 7. The company will also present a corporate update via a webcast at 8:00 am ET on the same day. Interested parties can register in advance on the company's website to participate.
Immunic is progressing with its lead program, vidofludimus calcium, which is undergoing clinical trials for various stages of multiple sclerosis and ulcerative colitis. This compound aims to combine neuroprotective, anti-inflammatory, and antiviral effects. The company's other developments include IMU-856 for gastrointestinal diseases and IMU-381 in preclinical testing.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Immunic AG